MedPath

Isolation of the Spermatic Cord in Mesh Inguinal Hernia Repair

Not Applicable
Conditions
Inguinal Hernia
Registration Number
NCT01391455
Lead Sponsor
Chatham Kent Health Alliance
Brief Summary

There are in excess of 1 million operations performed annually to repair inguinal hernias, mostly in the male population. Unfortunately, some patients continue to suffer both groin or testicular pain for varying lengths of time postoperatively. This can lead to a severe degradation of the patient's lifestyle, work habits and sexual function. The origin of the pain is felt to be secondary to the inflammatory reaction caused by the mesh. This also involves the spermatic cord and its structures, leading to orchidinia and possibly azospermia.

Detailed Description

In this prospective randomized trial, male patients with a primary symptomatic unilateral inguinal hernia will be admitted to the trial. All patients must be over 21 years of age. In order to avoid inguinal nerve entrapment or damage by mesh fixation sutures Covidien Parietene ProGrip mesh will be employed. This mesh does not require fixation. Standard open inguinal hernia repair will take place with nerve preservation, as day surgery cases. In the randomized portion of the study, the mesh will be placed as usual along the posterior wall of the inguinal canal, however the inguinal ligament will be interposed between the mesh and the spermatic cord, thus isolating the cord from intimate contact with the mesh, and a reduction in postoperative inflammatory changes.

Recruitment & Eligibility

Status
UNKNOWN
Sex
Male
Target Recruitment
220
Inclusion Criteria
  • Clinical diagnosis of a primary unilateral inguinal hernia
Exclusion Criteria
  • Medically unfit for surgical repair

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Evaluation of groin or testicular pain lasting longer than 3 months postoperatively.1 year postoperatively

All patients will be evaluated using the Carolina's Comfort Scale

Secondary Outcome Measures
NameTimeMethod
Number of patients with adverse events.1 year

Trial Locations

Locations (1)

Chatham Kent Health Alliance

🇨🇦

Chatham, Ontario, Canada

Chatham Kent Health Alliance
🇨🇦Chatham, Ontario, Canada
John A Morrison, MD;FRCS(C)
Contact
519 352 0503
hernia@johnmorrisonmd.com
Gary Tithecott, MD;FRCP(C)
Contact
519 3526400
gtithecott@ckha.on.ca
John A Morrison, MD;FRSC(C)
Principal Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.